130 related articles for article (PubMed ID: 8045141)
41. Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A.
van Dissel JT; van Furth R; Compier BA; Feuth HD; Frolich M
Lancet; 1993 Apr; 341(8850):959-60. PubMed ID: 8096292
[No Abstract] [Full Text] [Related]
42. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J;
Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753
[TBL] [Abstract][Full Text] [Related]
43. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
Dhainaut JF; Laterre PF; LaRosa SP; Levy H; Garber GE; Heiselman D; Kinasewitz GT; Light RB; Morris P; Schein R; Sollet JP; Bates BM; Utterback BG; Maki D
Crit Care Med; 2003 Sep; 31(9):2291-301. PubMed ID: 14501959
[TBL] [Abstract][Full Text] [Related]
44. Role of immunomodulator therapy in sepsis.
Caplan ES
Am J Surg; 1993 Feb; 165(2A Suppl):20S-25S. PubMed ID: 8438996
[TBL] [Abstract][Full Text] [Related]
45. Reactivity of the human antiendotoxin immunoglobulin M monoclonal antibody HA-1A with lipopolysaccharides from rough and smooth gram-negative organisms.
Mascelli MA; Frederick B; Ely T; Neblock DS; Shealy DJ; Pak KY; Daddona PE
Infect Immun; 1993 May; 61(5):1756-63. PubMed ID: 8478065
[TBL] [Abstract][Full Text] [Related]
46. Monoclonal antibodies to endotoxin in the management of sepsis.
Fang KC
West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
[TBL] [Abstract][Full Text] [Related]
47. Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators.
Seino Y; Momomura S; Takano T; Hayakawa H; Katoh K
Crit Care Med; 1996 Sep; 24(9):1490-7. PubMed ID: 8797620
[TBL] [Abstract][Full Text] [Related]
48. Centoxin: the full story of its withdrawal.
Choyce MQ
Br J Hosp Med; 1993 Apr 7-20; 49(7):517. PubMed ID: 8490694
[No Abstract] [Full Text] [Related]
49. Cost-effectiveness of HA-1A treatment for patients with sepsis.
van Hout BA; Birnie E; Redekop WK; Lorijn RH; Bossuyt PM; Rutten FF
Prog Clin Biol Res; 1994; 388():435-43. PubMed ID: 7831376
[TBL] [Abstract][Full Text] [Related]
50. Prostacyclin is neither sufficient alone nor necessary to cause pulmonary dysfunction: results from infusions of prostacyclin and antiprostacyclin antibody in porcine septic shock.
Tran HS; Quinn JV; Puc MM; Woolley DS; Puglisi RN; Slotman GJ
Crit Care Med; 2001 Jul; 29(7):1445-51. PubMed ID: 11445706
[TBL] [Abstract][Full Text] [Related]
51. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
Cohen J; Carlet J
Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
[TBL] [Abstract][Full Text] [Related]
52. The economic impact of HA-1A (Centoxin) against endotoxin.
Barriere SL
Pharmacoeconomics; 1992 Nov; 2(5):408-13. PubMed ID: 10147053
[TBL] [Abstract][Full Text] [Related]
53. Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction.
Wagner F; Yeter R; Bisson S; Siniawski H; Hetzer R
Crit Care Med; 2003 May; 31(5):1421-8. PubMed ID: 12771613
[TBL] [Abstract][Full Text] [Related]
54. Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.
Bogard WC; Siegel SA; Leone AO; Damiano E; Shealy DJ; Ely TM; Frederick B; Mascelli MA; Siegel RC; Machielse B
J Immunol; 1993 May; 150(10):4438-49. PubMed ID: 7683319
[TBL] [Abstract][Full Text] [Related]
55. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.
Briegel J; Forst H; Haller M; Schelling G; Kilger E; Kuprat G; Hemmer B; Hummel T; Lenhart A; Heyduck M; Stoll C; Peter K
Crit Care Med; 1999 Apr; 27(4):723-32. PubMed ID: 10321661
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
57. Antibody to endotoxin in the treatment of gram-negative sepsis.
Schentag JJ
JAMA; 1992 May; 267(17):2326-7. PubMed ID: 1564766
[No Abstract] [Full Text] [Related]
58. Antibody to endotoxin in the treatment of gram-negative sepsis.
Spalter J
JAMA; 1992 May; 267(17):2325; author reply 2326. PubMed ID: 1564764
[No Abstract] [Full Text] [Related]
59. Experimental gut-derived endotoxaemia and bacteraemia are reduced by systemic administration of monoclonal anti-LPS antibodies.
Gianotti L; Braga M; Vaiani R; Almondo F; Di Carlo V
Burns; 1996 Mar; 22(2):120-4. PubMed ID: 8634118
[TBL] [Abstract][Full Text] [Related]
60. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5.
Marra MN; Thornton MB; Snable JL; Wilde CG; Scott RW
Crit Care Med; 1994 Apr; 22(4):559-65. PubMed ID: 8143464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
